HAEMOPHILIA IN SWEDEN .3. SYMPTOMATOLOGY, WITH SPECIAL REFERENCE TO DIFFERENCES BETWEEN HAEMOPHILIA A AND B

被引：0
|
作者：
RAMGREN, O
机构：
来源：
ACTA MEDICA SCANDINAVICA | 1962年 / 171卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：237 / +
相关论文
共 50 条
  • [21] On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden:: differences in treatment characteristics and outcome
    Carlsson, KS
    Höjgård, S
    Glomstein, A
    Lethagen, S
    Schulman, S
    Tengborn, L
    Lindgren, A
    Berntorp, E
    Lindgren, B
    HAEMOPHILIA, 2003, 9 (05) : 555 - 566
  • [22] Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B) : a multicentre, open-label, randomised, phase 3 trial
    Srivastava, Alok
    Rangarajan, Savita
    Kavakli, Kaan
    Klamroth, Robert
    Kenet, Gili
    Khoo, Liane
    You, Chur-Woo
    Xu, Weiqun
    Malan, Niel
    Frenzel, Laurent
    Bagot, Catherine N.
    Stasyshyn, Oleksandra
    Chang, Chia-Yau
    Poloskey, Stacey
    Qiu, Zhiying
    Andersson, Shauna
    Mei, Baisong
    Pipe, Steven W.
    LANCET HAEMATOLOGY, 2023, 10 (05): : E322 - E332
  • [23] Comparing bleed frequency and factor concentrate use between haemophilia A and B patients
    Nagel, K.
    Walker, I.
    Decker, K.
    Chan, A. K. C.
    Pai, M. K.
    HAEMOPHILIA, 2011, 17 (06) : 872 - 874
  • [24] Special Issue: The Second Advanced Haemophilia Course, Genarp/Malmo, Sweden 2013-2014: Students' Presentations Introduction
    Berntorp, Erik
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 94 : 1 - 1
  • [25] Long-Term Course of the Severe Haemophilia A or B Patients in Sweden: Results from a Cohort Register Study
    Lovdahl, Susanna
    Berntorp, Erik
    Henriksson, Karin M.
    Astermark, Jan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 111 - 111
  • [26] Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment
    Mantovani, LG
    Monzini, MS
    Mannucci, PM
    Scalone, L
    Villa, M
    Gringeri, A
    HAEMOPHILIA, 2005, 11 (06) : 589 - 597
  • [27] SUBCUTANEOUS CONCIZUMAB PROPHYLAXIS IN PATIENTS WITH HAEMOPHILIA A OR B WITH INHIBITORS: EFFICACY AND SAFETY RESULTS BY HAEMOPHILIA SUBTYPE FROM THE PHASE 3 EXPLORER7 TRIAL
    Mathias, M.
    Cepo, K.
    d'Oiron, R.
    Frei-Jones, M.
    Goh, A. -S.
    Odgaard-Jensen, J.
    HAEMOPHILIA, 2023, 29 : 17 - 17
  • [28] Discrepancies between the one-stage clotting assay and the chromogenic assay in haemophilia B
    Kihlberg, Kristina
    Strandberg, Karin
    Ljung, Rolf
    Berntorp, Erik
    Astermark, Jan
    HAEMOPHILIA, 2016, 22 : 70 - 70
  • [29] Discrepancies between the one-stage clotting assay and the chromogenic assay in haemophilia B
    Kihlberg, K.
    Strandberg, K.
    Rosen, S.
    Ljung, R.
    Astermark, J.
    HAEMOPHILIA, 2017, 23 (04) : 620 - 627
  • [30] Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial
    Young, Guy
    Srivastava, Alok
    Kavakli, Kaan
    Ross, Cecil
    Sathar, Jameela
    You, Chur-Woo
    Tran, Huyen
    Sun, Jing
    Wu, Runhui
    Poloskey, Stacey
    Qiu, Zhiying
    Kichou, Salim
    Andersson, Shauna
    Mei, Baisong
    Rangarajan, Savita
    LANCET, 2023, 401 (10386): : 1427 - 1437
12345